Dyne Therapeutics (DYN) AI Stock Analysis

• Market Cap: $3.00B
• Dividend Yield: N/A
• Average Volume (3M): 2.49M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: N/A
• EPS Growth: -2.75%
• Country: US
• Employees: 192
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.76
• Shares Outstanding: 165,027,110
• 10 Day Avg. Volume: 2,283,770
• 30 Day Avg. Volume: 2,486,007
• PEG Ratio: -1.90
• Price to Book (P/B): 2.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.20
• Enterprise Value/Market Cap: 0.72
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.15K
• Enterprise Value/Ebitda: -4.93
• 1Y Price Target: $39.57
• Price Target Upside: 117.90% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -3.16
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $17.50 ▼(-3.63% Downside)
• Action: Reiterated Date: 03/11/26
• Date: Action: Reiterated 03/11/26

The score is primarily constrained by continued pre-revenue operations with widening losses and accelerating cash burn, despite a strong, low-leverage balance sheet. Technicals show an uptrend but with mixed momentum signals, while valuation support is limited due to a negative P/E and no dividend. Corporate updates are positive, citing encouraging clinical progress and significant cash runway.

Positive Factors

Targeted delivery platform (FORCE)

Dyne's FORCE platform is a structural competitive asset: durable targeted-delivery capability to muscle tissue can raise clinical success probabilities across multiple programs, enable platform-based pipeline expansion and partnerships, and create a technological moat that supports long-term commercial differentiation.

Negative Factors

Pre-revenue with widening losses

Persistent pre-revenue status with rapidly widening losses is a foundational risk: without product sales, the company must continuously fund R&D and operations externally. Ongoing negative profitability over multiple years pressures returns and heightens reliance on successful clinical outcomes and financing events.

Dyne Therapeutics Business Overview & Revenue Model

Company Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, ...

Read more

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, ...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, Dyne’s revenue, when present, is primarily generated from collaborations and licensing arrangements (e.g., upfront payments, research funding, and potential development, regulatory, and sales-based mi...

Read more

As a clinical-stage biopharmaceutical company, Dyne’s revenue, when present, is primarily generated from collaborations and licensing arrangements (e.g., upfront payments, research funding, and potential development, regulatory, and sales-based mi...

Dyne Therapeutics Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.05M	-2.24M	-2.46M	0.00	0.00
EBITDA	-437.97M	-315.18M	-233.48M	-169.28M	-148.94M
Net Income	-446.21M	-317.42M	-235.94M	-168.10M	-149.29M
Balance Sheet
Total Assets	1.19B	691.23M	165.08M	306.32M	425.66M
Cash, Cash Equivalents and Short-Term Investments	1.11B	642.27M	123.10M	256.01M	376.57M
Total Debt	20.28M	23.99M	27.41M	30.48M	32.64M
Total Liabilities	214.83M	61.40M	73.79M	53.96M	57.47M
Stockholders Equity	972.13M	629.84M	91.29M	252.36M	368.20M
Cash Flow
Free Cash Flow	-405.13M	-294.75M	-188.89M	-156.71M	-123.18M
Operating Cash Flow	-403.21M	-292.37M	-188.16M	-153.65M	-119.56M
Investing Cash Flow	-28.75M	-204.08M	83.31M	87.20M	-137.89M
Financing Cash Flow	890.31M	809.89M	54.32M	37.39M	157.82M

Dyne Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.16
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYN, the sentiment is Positive. The current price of 18.16 is below the 20-day moving average (MA) of 18.26, above the 50-day MA of 17.20, and above the 200-day MA of 15.69, indicating a neutral trend. The MACD of 0.32 indicates Positive momentum. The RSI at 52.80 is Neutral, neither overbought nor oversold. The STOCH value of 65.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DYN.

Dyne Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	63 Neutral	$2.89B	-228.91	-10.26%	―	129.21%	80.35%
DYN	56 Neutral	$3.00B	-5.63	-61.45%	―	―	-2.75%
BEAM	54 Neutral	$2.49B	-34.27	-7.31%	―	-84.07%	-157.71%
SRPT	53 Neutral	$2.42B	-3.16	-57.52%	―	47.15%	-311.26%
IMCR	53 Neutral	$1.62B	-19.61	-6.93%	―	27.51%	38.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
COGT	46 Neutral	$5.78B	―	-100.22%	―	―	4.32%

Dyne Therapeutics Corporate Events